A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations in the Presence of a Baseline Covariate

Figure 3

Pointwise percent of MTD recommendation for with designs using a covariate (WC), ignoring the covariate (IC), and parallel trials (PT) under scenarios (a)-(d).